Semaglutide for Weight Loss: How the Most Talked-About Peptide Works

Few medical treatments have generated as much public attention as semaglutide. Known by brand names like Ozempic and Wegovy, this peptide has fundamentally changed how the medical community approaches obesity and metabolic disease. But what is semaglutide, exactly, and why does it work so well?

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. In plain terms, it is a synthetic peptide that mimics a naturally occurring hormone in your gut called GLP-1. Your intestine releases GLP-1 after you eat — it signals your pancreas to release insulin, tells your brain you're full, and slows down how quickly food moves through your stomach.

Semaglutide is structurally similar to natural GLP-1 but engineered to last much longer. Natural GLP-1 is broken down in the bloodstream within 2 minutes. Semaglutide resists this degradation and, depending on the formulation, stays active for about a week — which is why it can be dosed as a once-weekly injection.

Why Does It Cause Weight Loss?

Semaglutide produces weight loss through multiple simultaneous pathways, which is a key reason it outperforms older weight loss medications:

Brain appetite regulation. Semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamus and brainstem — the brain's appetite control centers. It reduces the drive to eat, specifically decreasing cravings for high-fat and high-calorie foods. Many patients describe thinking about food less and feeling satisfied with smaller portions.

Gastric emptying. By slowing the rate at which food leaves the stomach and enters the small intestine, semaglutide prolongs the physical feeling of fullness after meals. This reduction in gastric emptying rate is dose-dependent.

Reward pathway modulation. Research suggests semaglutide also acts on dopamine circuits involved in food reward — reducing the pleasure drive associated with eating, which is a central challenge in obesity.

Insulin sensitivity improvement. Semaglutide improves how effectively the body uses insulin, reducing fat storage driven by hyperinsulinemia.

What Do the Clinical Trials Show?

The evidence base for semaglutide in weight loss is among the strongest of any pharmacological treatment for obesity:

STEP 1 Trial (68 weeks, 2021). 1,961 adults with obesity received 2.4 mg semaglutide weekly or placebo. The semaglutide group lost an average of 14.9% of body weight. Over one-third of participants lost more than 20% of their body weight.

STEP 4 Trial (2021). Participants who lost weight on semaglutide and then switched to placebo regained two-thirds of the lost weight within a year — confirming that obesity is a chronic condition requiring ongoing treatment, not a one-time fix.

SELECT Trial (2023). This landmark cardiovascular outcomes trial enrolled 17,604 adults with cardiovascular disease and obesity (but not diabetes). Semaglutide reduced major adverse cardiovascular events by 20% and all-cause mortality by 19% — establishing that the benefits extend well beyond weight loss.

How Is Semaglutide Administered?

For weight loss (Wegovy): 2.4 mg weekly subcutaneous injection, following a 16-week dose escalation starting at 0.25 mg/week.

For diabetes (Ozempic): 0.5 mg to 2.0 mg weekly subcutaneous injection.

An oral form (Rybelsus) is available for diabetes management at 7-14 mg daily, though bioavailability is lower than the injectable form.

Side Effects: What to Expect

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These are most prominent during dose escalation and typically diminish over time. Approximately 4-6% of participants in clinical trials discontinued due to GI side effects.

Less common but noted effects include:

• Mild heart rate increase (average 2-4 bpm)
• Injection site reactions
• Rare pancreatitis risk (estimated <0.3% per year)
• Possible gallstone formation (due to rapid weight loss)

The much-discussed "Ozempic face" (facial volume loss with rapid weight loss) is a consequence of fast fat loss, not a direct peptide effect.

Who Is It For?

Semaglutide (Wegovy) is FDA-approved for adults with a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, or cardiovascular disease).

The Bottom Line

Semaglutide represents a genuine advance in metabolic medicine. It works by addressing both the biological and behavioral drivers of overeating, produces weight loss that exceeds lifestyle intervention alone, and reduces cardiovascular risk independently of weight loss. Its limitations — ongoing need for treatment and GI side effects during initiation — are real but manageable for most patients with proper medical supervision.